

BLACK

BLACK

**Norflex**
*Gel*SCHEDULING STATUS
S1
PROPRIETARY NAME AND
DOSAGE FORM
NORFLEX GEL**COMPOSITION**

Each 100 g contains: Benzydamine hydrochloride 3,0 g.
Other ingredients include glycerol, hydroxyethyl cellulose,
isopropyl alcohol, lavender perfume and purified water.

PHARMACOLOGICAL CLASSIFICATION

A 3.1 Antirheumatics (anti-inflammatory) agents

PHARMACOLOGICAL ACTION

Benzydamine hydrochloride is a non-steroidal, anti-inflammatory agent and exerts a local anti-inflammatory, and analgesic action.

NORFLEX GEL is well absorbed through the skin.

INDICATIONS

NORFLEX GEL is recommended as a short-term treatment for the symptomatic relief of painful inflammatory conditions of the musculo-skeletal system, including:

Acute inflammatory conditions such as myalgia and bursitis. Traumatic conditions such as sprains, strains, contusions and the after-effects of fractures.

CONTRAINDICATIONS

Hypersensitivity to benzydamine hydrochloride.
Safety in pregnancy and lactation has not been established.

WARNINGS AND SPECIAL PRECAUTIONS

Avoid contact with eyes and mucosal surfaces.

DOSAGE AND DIRECTIONS FOR USE

NORFLEX GEL should be massaged lightly into the area three times daily, up to six times daily in more severe conditions (at the discretion of your doctor).

35 to 85 mm (1 to 2,5 g) should be used for each application. Do not use continuously for longer than 10 days without consulting your doctor.

SIDE EFFECTS

Photosensitivity reactions have been reported.
Local skin reactions ranging from erythema to papular eruptions.
The skin may return to normal on stopping treatment.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT

See **SIDE EFFECTS**.

On accidental ingestion, the following symptoms may appear:

Tissue numbness, a stinging or burning sensation, lightheadedness, nausea, vomiting and an altered sense of taste.

Treatment is symptomatic and supportive.

IDENTIFICATION

Clear colourless to slightly opalescent gel with an odour of lavender or isopropyl alcohol.

PRESENTATION

White aluminium laminated tubes containing 30 g or 75 g.

STORAGE INSTRUCTIONS

Store at or below 30 °C.
Protect from light.
KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER

32/3.1/0547

NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION

iNova Pharmaceuticals (Pty) Ltd
15E Riley Road, Bedfordview, 2007

DATE OF PUBLICATION OF THIS PACKAGE INSERT

26 September 2001

LTO89.04.17

BLACK

BLACK

Norflex
*Gel*SKEDULERINGSTATUS
S1
EIENDOMSNAAM EN
DOSEERVORM
NORFLEX GEL**SAMESTELLING**

Elke 100 g bevat: Bensidamienhydrochloried 3,0 g.
Ander bestanddele sluit gliserol, hidroksie etielsellulose,
isopropiel alkohol, laventel geur en gesuiwerde water in.

FARMAKOLOGIESE KLASSIFIKASIE

A 3.1 Rumatiek (anti-inflammatoriese) middels

FARMAKOLOGIESE WERKING

Bensidamienhydrochloried is 'n nie-steroidale, anti-inflammatoriese agent wat 'n plaaslike anti-inflammatoriese en analgetiese aksie uitoefen.

NORFLEX GEL word goed deur die vel geabsorbeer.

INDIKASIES

NORFLEX GEL is aangedui as kort-termyn behandeling vir die simptomiese verligting van pynlike inflammatoriese kondisies van die muskulo-skeletale sisteem, insluitende: Akute inflammatoriese toestande soos mialgie en bursitis. Traumatiese toestande soos verstuiting, verrekking, kneusing en die nagevolge van frakture.

KONTRA-INDIKASIES

Hipersensitieweit vir bensidamienhydrochloried.
Die veiligheid in swangerskap en laktasie is nie vasgestel nie.

WAARSKUWINGS EN SPESIALE VOORSORGMATREËLS

Vermyn kontak met die oë en slymvliese.

DOSIS EN GEBRUIKSAANWYSINGS

Masseer **NORFLEX GEL** liggies in die area in drie keer per dag of tot ses keer per dag in meer ernstige toestande (volgens die dokter se diskresie). 35 tot 85 mm (1 tot 2,5 g) behoort gebruik te word met elke aanwending.

Moet nie aaneenlopend vir langer as 10 dae gebruik sonder om 'n dokter te spreek nie.

NEWE-EFFEKTE

Fotosensitieweitreaksies is al gerapporteer.
Plaaslike vel reaksies varieer van eriteem tot papulêre uitslae.
Die vel mag na normaal terugkeer met staking van die behandeling.

BEKENDE SIMPTOME VAN OORDOSERING EN BESONDERHEDE VAN DIE BEHANDELING DAARVAN

Sien **NEWE-EFFEKTE**.

As dit per ongeluk ingesluk word, kan die volgende simptome tevore kom:

Weefsel verduwing, 'n steek of brand sensasie, lighoofdigheid, naarheid, braking en 'n veranderde sin van smaak.
Behandeling is simptomaties en ondersteunend.

IDENTIFIKASIE

Helder, kleurlose tot effens melkerige jel met 'n reuk van laventel of isopropiel alkohol.

AANBIEDING

Wit, aluminium, gelamineerde buise bevattend 30 g of 75 g.

BERGINGSAAWYSINGS

Bewaar teen of benede 30 °C.
Beskerm teen lig.
HOU BUITE BEREIK VAN KINDERS.

REGISTRASIENOMMER

32/3.1/0547

NAAM EN BESIGHEIDSADRES VAN DIE HOUER VAN DIE REGISTRASIESERTIFIKAAT

iNova Pharmaceuticals (Pty) Ltd
Rileyweg 15E, Bedfordview, 2007

DATUM VAN PUBLIKASIE VAN HIERDIE VOUBILJET

26 September 2001

